Bayer HealthCare

Bayer's Perspective on Innovation 2008

| 1 - 12 |

1879 KB

With the help of a gas-phase chromatograph laboratory assistant Edith Klein examines the vitamin E concentration in processed Renalzin samples at the analytics-lab of Bayer Animal Health in Monheim, Germany.
2141 KB

With Renalzin® Bayer Animal Health has developed a dietary supplement for the management of chronic renal diseases in cats.
1161 KB

Product developer Petra Ohage-Spitzlei (in the foreground) mixes a Renalzin suspension at the galenics-lab of of Bayer Animal Health in Monheim, Germany.
200 KB

left: Positron emission tomography (PET) image of the brain from a patient with Alzheimer‘s disease, marked with the pigment 18F-BAY94-9172. The yellow marked amyloid plaques already appear in an early stage of the disease. right: PET image of a healthy patient, also marked with the pigment 18F-BAY94-9172.
1115 KB

Xarelto developer Dr. Elisabeth Perzborn.
1212 KB

Cardiac cell cultures: to ensure that there is enough material for testing, cardiac cells are cultured.
1298 KB

Heartache: during angina pectoris attacks, regulations of the heart beat runs out of control.
298 KB

One molecule of Xarelto blocking the active site of a Factor Xa protein.
1119 KB

Dr. Ludger Dinkelborg (l.) and his colleague Dr. Thomas Dyrks, are comparing the pictures of a healthy brain (left display) with the picture of a brain of an Alzheimer patient.
1457 KB

High-tech manual work: Detlef Neunherz, a technician in the robot team at Bayer HealthCare, prepares samples for high-throughput screening. The development of the anti-thrombosis drug Xarelto® is proof of how advanced technology and interdisciplinary collaboration between experienced chemists can be combined to achieve success.
1468 KB

Alexander Korseska and Nina Habrich at Direvo Biotech AG check the new sequence of movements for a high-throughput screening robot.
1327 KB

Although most of the steps in the high-throughput screening process are carried out automatically, Dr. Carsten Bäumchen from Direvo Biotech AG still needs to check the results.

| 1 - 12 |

top

Search

Advanced Search

Publications

Stockholders' Newsletter

Sustainable Development Report

The Bayer Climate Program

research – The Bayer Scientific Magazine

Publications Overview

Newsletter

We will keep you informed about the latest news.

Events

Thursday, April 29, 2010

Q1 2010 Interim Report

Contact: Günter Forneck

Additional Press Events

Investor Relations Events

Download Center - Selection

Your selection:
0
Download(s)